For example, primary analyses identified higher GSTM4 was associated with a lower risk of bladder cancer [OR: 0.81, 95% CI: 0.74 to 0.89, PP4: 0.99] in main analyses, which was replicated in a combined bladder cancer GWAS from UK Biobank and Finngen cohorts [OR: 0.85, 95% CI: 0.77 to 0.93]. Here, GSTM4 is linked to urinary bladder cancer.